<DOC>
	<DOC>NCT00329589</DOC>
	<brief_summary>The purpose of this study is to determine the safety of Velcade when used with chemoradiation in cancer patients.</brief_summary>
	<brief_title>A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients</brief_title>
	<detailed_description>- To determine the maximum tolerated dose (MTD) and a recommended phase II dose (RP2D) of Velcade® when administered as a twice weekly 3-5 second IV bolus every 3 weeks to patients with malignancies of the brain, head and neck and cervix who receive 2-8 weeks of chemoradiation. - To evaluate the safety and toxicity profile of Velcade® when administered on a twice weekly (days 1, 4, 8 and 11) every 3 weeks (maximum 8 weeks) concurrent with chemoradiation. - To evaluate tumor response</detailed_description>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirmed malignancy Requiring at least grade 2 weeks of radiation therapy Solid tumors of the central nervous system, head and neck area, and cervix World Health Organization (WHO) performance status equal to or less than 2 Equal to or greater than grade 2 peripheral neuropathy Myocardial infarction within 6 months Hypersensitivity to bortezomib, boron, or mannitol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Malignancies of the central nervous system, head and neck area</keyword>
	<keyword>and cervix</keyword>
</DOC>